Cancer therapy and cardiovascular risk: focus on bevacizumab

Cancer therapy and cardiovascular risk: focus on bevacizumab

Panagiota Economopoulou,1 Athanasios Kotsakis,2 Ioannis Kapiris,3 Nikolaos Kentepozidis3 1Medical Oncology Unit, 2nd Department of Internal Medicine, Attikon University Hospital, Haidari, Athens, 2Department of Medical Oncology, University Hospital of Heraklion, Crete, 3251 Airforce General Hospital...

Full description

Bibliographic Details
Main Authors:	Economopoulou P, Kotsakis A, Kapiris I, Kentepozidis N
Format:	Article
Language:	English
Published:	Dove Medical Press 2015-06-01
Series:	Cancer Management and Research
Online Access:	http://www.dovepress.com/cancer-therapy-and-cardiovascular-risk-focus-on-bevacizumab-peer-reviewed-article-CMAR

Similar Items

Breast cancer therapy and cardiovascular risk: focus on trastuzumab
by: Sandoo A, et al.
Published: (2015-04-01)

Front-Line Bevacizumab plus Chemotherapy with or without Maintenance Therapy for Metastatic Breast Cancer: An Observational Study by the Hellenic Oncology Research Group
by: Stefania Kokkali, et al.
Published: (2022-02-01)

Bevacizumab in maintenance therapy for ovarian cancer patients
by: L. Yu. Vladimirova, et al.
Published: (2020-08-01)

Anti-angiogenetic agents against tumor types and cardiovascular risk
by: Panagiota Economopoulou, et al.
Published: (2017-05-01)

Factors Associated with Adverse Cardiovascular Events in Cancer Patients Treated with Bevacizumab
by: Doan T. M. Ngo, et al.
Published: (2020-08-01)

Bevacizumab in the therapy for refractory metastatic colorectal cancer
by: Mary F Mulcahy
Published: (2008-03-01)

Advances in Bevacizumab Therapy of Primary Lung Cancer
by: Jun PEI, et al.
Published: (2009-02-01)

Cancer-Associated Thrombosis on Bevacizumab: Risk of Recurrence and Bleeding When Bevacizumab Is Stopped or Continued
by: Marie Mayenga, et al.
Published: (2023-07-01)

CLINICAL EXPERIENCE OF PROLONGED BEVACIZUMAB THERAPY IN METASTATIC COLORECTAL CANCER
by: I. S. Bulavina, et al.
Published: (2015-02-01)

Early Prediction of Response Focused on Tumor Markers in Atezolizumab plus Bevacizumab Therapy for Hepatocellular Carcinoma
by: Norikazu Tanabe, et al.
Published: (2023-05-01)

Bevacizumab increases the incidence of cardiovascular events in patients with metastatic breast or colorectal cancer
by: Ioannis Kapelakis, et al.
Published: (2017-05-01)

Role of bevacizumab therapy in the management of glioblastoma
by: Scott J Peak, et al.
Published: (2010-04-01)

Atezolizumab and Bevacizumab Combination Therapy in the Treatment of Advanced Hepatocellular Cancer
by: Ignacio Ventura, et al.
Published: (2023-12-01)

Bevacizumab and ovarian cancer
by: Agustin Garcia, et al.
Published: (2013-03-01)

A New Bevacizumab Carrier for Intravitreal Administration: Focus on Stability
by: Daniela Chirio, et al.
Published: (2021-04-01)

Remission of psoriasis and psoriatic arthritis during bevacizumab therapy for renal cell cancer
by: Ananaya Datta-Mitra, et al.
Published: (2014-01-01)

Pharmacogenetics in Model-Based Optimization of Bevacizumab Therapy for Metastatic Colorectal Cancer
by: Apostolos Papachristos, et al.
Published: (2020-05-01)

Bowel Perforation in the Emergency Department Related to Bevacizumab Therapy and Recurrent Ovarian Cancer
by: Stuart A. Ostby, et al.
Published: (2020-05-01)

Update and developments in the treatment of glioblastoma multiforme &ndash; focus on bevacizumab
by: Naveed Wagle, et al.
Published: (2010-06-01)

Pustular psoriasis triggered by therapy with atezolizumab and bevacizumab
by: Mariani Magnus da Luz Andrade, et al.
Published: (2024-01-01)

Predictive Biomarkers for Bevacizumab in Anti-tumor Therapy
by: Qingqing PAN, et al.
Published: (2011-07-01)

Bevacizumab increases the risk of anastomosis site leakage in metastatic colorectal cancer
by: Seijong Kim, et al.
Published: (2022-10-01)

Bevacizumab induced hypertension in gynecologic cancer: Does it resolve after completion of therapy?
by: Bradley R. Corr, et al.
Published: (2016-08-01)

Acceptable Safety of Bevacizumab Therapy in Combination with Chemotherapy in Patients with Advanced Lung Cancer
by: Wei WU, et al.
Published: (2009-03-01)

Targeting the Interplay between HDACs and DNA Damage Repair for Myeloma Therapy
by: Maria Gkotzamanidou, et al.
Published: (2021-09-01)

Biomarkers to predict the clinical efficacy of bevacizumab in cancer.
by: Jubb, A, et al.
Published: (2010)

Preliminary results of an observational program for estimating the duration of bevacizumab therapy in patients with metastatic colorectal cancer in daily clinical practice
by: I V Poddubnaya, et al.
Published: (2013-03-01)

Cardiovascular Risk in Children: Focus on Pathophysiological Aspects
by: Simonetta Genovesi, et al.
Published: (2020-09-01)

Critical appraisal of bevacizumab in the treatment of ovarian cancer
by: Yoshida H, et al.
Published: (2015-04-01)

Results of preoperative antitumor therapy in combination with bevacizumab and KRAS status during liver resections for colorectal cancer metastases
by: M I Sekacheva, et al.
Published: (2013-06-01)

Postoperative bronchopleural fistula after induction therapy with bevacizumab
by: Hironobu Wada, et al.
Published: (2023-08-01)

Clinical course of severe esophagitis following bevacizumab therapy
by: Jun-Ho Choi, et al.
Published: (2022-01-01)

Posterior reversible encephalopathy syndrome (PRES) after bevacizumab therapy for metastatic colorectal cancer
by: Mohsin Hamid, et al.
Published: (2018-05-01)

Two Cases of Mastectomy after Paclitaxel + Bevacizumab Therapy for Locally Advanced Breast Cancer
by: Chika Shinoda, et al.
Published: (2014-05-01)

Remission of psoriasis and psoriatic arthritis during bevacizumab therapy for renal cell cancer: Erratum
Published: (2015-01-01)

The efficacy and safety of paclitaxel plus bevacizumab therapy in breast cancer patients with visceral crisis
by: Chikako Funasaka, et al.
Published: (2021-08-01)

An updated meta-analysis of fatal adverse events caused by bevacizumab therapy in cancer patients.
by: Hongxin Huang, et al.
Published: (2014-01-01)

Cardiovascular complications in patients with cancer: focus on anthracycline-induced cardiotoxicity
by: I. T. Murkamilov, et al.
Published: (2021-03-01)

Outcome of Atezolizumab Plus Bevacizumab Combination Therapy in High-Risk Patients with Advanced Hepatocellular Carcinoma
by: Sang Youn Hwang, et al.
Published: (2024-02-01)

Phase I/II trial of bevacizumab and radiotherapy for locally advanced inoperable colorectal cancer: vasculature-independent radiosensitizing effect of bevacizumab.
by: Koukourakis, M, et al.
Published: (2009)